Hanmi Pharmaceutical Unveiled Cancer Treatment Research

The company presented preclinical findings for a drug conjugate targeting fibroblast activation protein.

Updated on Oct. 6, 2026 in Cancer

A close-up view of clear medical vials in a metal laboratory rack on a white surface. — Hanmi Pharmaceutical has reported new preclinical research for a small-molecule drug conjugate designed to target solid tumors and improve therapeutic efficacy. AI Illustration. Upload story photo >

Live Poll

Do you believe targeting the tumor microenvironment is a promising path for new cancer treatments?

Hanmi Pharmaceutical has showcased new preclinical research for a small-molecule drug conjugate designed to target the tumor microenvironment. The candidate aims to improve therapeutic reach by focusing on fibroblast activation protein.

Why it matters

This approach seeks to bypass the limitations of antibody-drug conjugates, specifically the challenges associated with large molecule size and poor tissue penetration. By targeting the tumor microenvironment, the drug may offer an alternative strategy for attacking solid tumors.

Preclinical studies involving mouse models demonstrated tumor growth inhibition and extended survival. Researchers utilized DNA-Encoded Library screening technology to identify the small-molecule compound.

The players

Hanmi Pharmaceutical

This is a South Korean-based pharmaceutical company that focuses on developing innovative therapies for cancer and metabolic diseases.

The details

The drug conjugate connects a cytotoxic drug to a small-molecule binder that remains stable in the bloodstream. It is specifically engineered to release its payload only after reaching fibroblast activation protein within the tumor microenvironment.

September 28, 2026: Discovery on Target 2026 event began in Boston.
October 1, 2026: Discovery on Target 2026 event concluded.
October 6, 2026: Hanmi Pharmaceutical presented preclinical research results.
October 6, 2026: Nature Conference presentation begins in Texas.
October 8, 2026: Nature Conference presentation concludes.

Cancer
Sept. 21
FDA Conditionally Accepted Name for Lirafugratinib
Cancer
Oct. 1
FDA to Decide on Ivonescimab Approval by November 14
Cancer
Sept. 26
Merck and Daiichi Sankyo Withdrew Cancer Drug Bid

Deeper Dive

The use of DNA-Encoded Library screening technology marks a shift in how pharmaceutical companies identify small-molecule binders for complex tumor targets. This research follows a pattern of utilizing DNA-Encoded Library screening technology to accelerate the discovery of targeted drug candidates.

This development represents early-stage scientific progress that does not currently offer direct clinical treatment options for patients. Future potential benefits for patients depend on the successful completion of subsequent human safety and efficacy trials.

The takeaway

Targeting the tumor microenvironment provides a promising alternative to traditional therapies that focus solely on cancer cells. Continued refinement of small-molecule drug conjugates could lead to more effective treatments with better tissue penetration.

What happens next

The research results will be presented at the Nature Conference-Next Generation Cancer Therapeutics event occurring from October 6 through October 8, 2026.